Placebo for CAB LA

DRUG2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV Infections

Phase 2

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

CompletedNCT02720094

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2016-12-19End: 2025-03-31Updated: 2026-03-19

Phase 3

Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

Active, not recruitingNCT03164564

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2017-11-07End: 2026-10-17Updated: 2025-10-09

Related Papers

Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083.

2025-12-01

Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial.

2025-03-124 citations

Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis

UNC Libraries2025-01-25

Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084

Antimicrobial Agents and Chemotherapy2024-09-272 citations

Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP

Antimicrobial Agents and Chemotherapy2024-05-067 citations

Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.

2023-11-0942 citations

Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.

2023-09-296 citations

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.

2022-04-01401 citations

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

New England Journal of Medicine2021-08-11765 citations

Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.

2019-08-0871 citations

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

PLoS Medicine2018-11-08163 citations